Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Dr Reddy’s recalls four lots of Phytonadione injectable emulsion in US

3
SHARES

The FDA has announced that Dr Reddy’s is recalling Phytonadione injectable emulsion because of complaints due to ampules breaking and shattering.

Syringe in injectable emulsion

The US Food and Drug Administration (FDA) has announced that Dr Reddy’s Laboratories is voluntarily recalling four lots of its Phytonadione injectable emulsion USP, 10 mg/mL, single-dose ampules to the hospital level.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The product is being recalled because of complaints of ampules breaking and shattering, upon opening, during compounding.

According to the FDA, the company has received reports of cuts in skin and lacerations to health care professionals. There may be a reasonable probability that flying glass injuring skin, eye and/or other parts could result in either temporary or permanent injury.

The four lots being recalled are: ACB902, ACB903, ACB904 and ACB905. The batches were distributed nationwide in the US, between June 2019 and February 2020, to wholesalers, distributors, hospitals and pharmacies.

Phytonadione injectable emulsion is indicated for certain coagulation disorders including prophylaxis and therapy of hemorrhagic disease of the newborn and hypoprothrombinemia due to antibacterial therapy.

Dr Reddy’s Laboratories has also notified its distributors to arrange for return of any recalled product. Wholesalers, distributors, hospitals and pharmacies with an existing inventory of the lot being recalled should stop use and distribution of the product as well as quarantine the product immediately for return or replacement of all recalled products. 

More information about the recall can be found here. 

Share via
Share via